Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications
RT-qPCR is commonly used for virological endpoints during clinical trials for antiviral therapy to determine the quantity and presence of virus in a sample. However, RT-qPCR identifies viral RNA and cannot determine if viable virus is present. Existing culture-based techniques for SARS-CoV-2 are insensitive and not sufficiently standardized to be employed as clinical study endpoints. The use of a culture system to monitor replicating viruses could mitigate the possibility of molecular techniques identifying viral RNA from inactive or lysed viral particles. The methodology optimized in this study for detecting infectious viruses may have application as a secondary virological endpoint in clinical trials of therapeutics for SARS-CoV-2 in addition to numerous research processes.
Authors
- Rachel L. Byrne (ORCID: https://orcid.org/0000-0001-5398-3125)
- Susan Gould (ORCID: https://orcid.org/0000-0002-3722-867X)
- Christopher Myerscough
- Clare Lendrem (ORCID: https://orcid.org/0000-0002-9435-7398)
- Alessandra Romero-Ramirez (ORCID: https://orcid.org/0000-0002-8610-7815)
- Ana I. Cubas-Atienzar (ORCID: https://orcid.org/0000-0002-9604-124X)
- Barry Atkinson (ORCID: https://orcid.org/0000-0002-1348-7204)
- Charles Reynard (ORCID: https://orcid.org/0000-0002-7534-2668)
- Mary Logan (ORCID: https://orcid.org/0000-0003-1131-9714)
- Valerie Tate (ORCID: https://orcid.org/0009-0006-6640-2098)
- Gail Hayward (ORCID: https://orcid.org/0000-0003-0852-627X)
- Tom Fletcher (ORCID: https://orcid.org/0000-0002-3712-415X)
- Mark H. Wilcox (ORCID: https://orcid.org/0000-0002-4565-2868)
- Anna Halstead
- Brian K. Nicholson (ORCID: https://orcid.org/0000-0001-7334-0805)
- Bill Greenhalf
- Helen R. Savage (ORCID: https://orcid.org/0000-0003-2592-9257)
- Rafael Perera (ORCID: https://orcid.org/0000-0003-2418-2091)
- Adam J. Gordon (ORCID: https://orcid.org/0000-0002-2453-8871)
- Melody Zhifang
- Beverley Riley
- Kate Buist (ORCID: https://orcid.org/0000-0002-8004-6329)
- Paul M Dark (ORCID: https://orcid.org/0000-0003-3309-0164)
- Saye Khoo (ORCID: https://orcid.org/0000-0002-2769-0967)
- A. J. Simpson
- David Price (ORCID: https://orcid.org/0000-0002-0562-7326)
- Colette Inkson
- Andrew Lewington (ORCID: https://orcid.org/0000-0001-5504-0120)
- Charlotte J. Harden (ORCID: https://orcid.org/0000-0002-1897-2364)
- Naoko Jones
- Peter Buckle (ORCID: https://orcid.org/0000-0002-3985-2441)
- Victoria Shaw (ORCID: https://orcid.org/0000-0002-0429-0186)
- Thomas Edwards (ORCID: https://orcid.org/0000-0003-4058-4461)
- Dominic Wooding (ORCID: https://orcid.org/0000-0002-9985-0413)
- Richard Body
- Kerrie Davis
- Graham Prestwich (ORCID: https://orcid.org/0000-0002-6665-2090)
- Daniel S Lasserson (ORCID: https://orcid.org/0000-0001-8274-5580)
- Rachel Watkins
- William Jones (ORCID: https://orcid.org/0000-0002-4690-4852)
- Konstantina Kontogianni (ORCID: https://orcid.org/0000-0002-5353-3682)
- Massimo Micocci (ORCID: https://orcid.org/0000-0003-1750-120X)
- Daisy Bengey (ORCID: https://orcid.org/0000-0002-0045-0218)
- Caitlin R. Thompson (ORCID: https://orcid.org/0000-0003-1763-8863)
- Julian Braybrook
- Emily R. Adams (ORCID: https://orcid.org/0000-0002-0816-2835)
- Joseph Lee (ORCID: https://orcid.org/0000-0003-1897-6290)
- Philip J. Turner
- Austin Allen
- Caitlin Greenland-Bews
Institutions
- University of Liverpool (GB)
- Liverpool School of Tropical Medicine (GB)
- Royal Liverpool and Broadgreen University Hospital NHS Trust (GB)
- University of Oxford (GB)
- Manchester University NHS Foundation Trust (GB)
- UK Health Security Agency (GB)
Publication Details
- Journal
- mSphere
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1128/msphere.00304-24
- Citations
- 1
- Primary Topic
- SARS-CoV-2 detection and testing
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Department of Health and Social Care
- Imperial College London
- Medical Research Council